Last year's loss narrowed mainly due to cutting R&D? Staidson's performance remains under pressure | Interpretations

① In 2024, Staidson's total revenue has declined again, and the loss continues, with the company having incurred losses for five consecutive years so far. ② During the reporting period, the company's R&D investment was 0.162 billion yuan, a decrease of 63.77% compared to the same period last year, with most major R&D projects in early clinical trial stages.

cls.cnMar 24 10:23 ET

The FDA has once again delayed the approval for Jiangsu Hengrui Pharmaceuticals' PD-1 combination product.

Once again, it is a production compliance issue.

wallstreetcnMar 21 07:03 ET

The "Double Ai" therapy has encountered obstacles again in its launch in the USA. Jiangsu Hengrui Pharmaceuticals responded that they will "quickly resubmit the listing application after confirming the reasons."

① The "Double Ai" therapy has received a complete response letter from the FDA upon the second submission of the application; ② Jiangsu Hengrui Pharmaceuticals responded to reporters stating: they will promptly resubmit the application for market approval after confirming the reasons; ③ Experts say, "This is just a minor setback, production-related issues are easy to resolve."

cls.cnMar 21 06:32 ET

It is proposed to set aside a goodwill impairment provision of nearly 0.9 billion yuan. China National Accord Medicines Corporation's revenue and net profit are expected to decline in 2024 | Quick Announcement.

① Due to the combined impact of intensified market competition and other factors, China National Accord Medicines Corporation expects a decline in both revenue and Net income for 2024. ② The company plans to make an impairment provision totaling 1.094 billion yuan for credit impairment losses and asset impairment losses.

cls.cnMar 17 10:13 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET